These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32125749)

  • 1. Characteristics of fecal metabolic profiles in patients with irritable bowel syndrome with predominant diarrhea investigated using
    Lee JS; Kim SY; Chun YS; Chun YJ; Shin SY; Choi CH; Choi HK
    Neurogastroenterol Motil; 2020 Jun; 32(6):e13830. PubMed ID: 32125749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome.
    Zhang WX; Zhang Y; Qin G; Li KM; Wei W; Li SY; Yao SK
    World J Gastroenterol; 2019 Nov; 25(43):6416-6429. PubMed ID: 31798278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics analysis revealed metabolic changes in patients with diarrhea-predominant irritable bowel syndrome and metabolic responses to a synbiotic yogurt intervention.
    Noorbakhsh H; Yavarmanesh M; Mortazavi SA; Adibi P; Moazzami AA
    Eur J Nutr; 2019 Dec; 58(8):3109-3119. PubMed ID: 30392136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome.
    Le Gall G; Noor SO; Ridgway K; Scovell L; Jamieson C; Johnson IT; Colquhoun IJ; Kemsley EK; Narbad A
    J Proteome Res; 2011 Sep; 10(9):4208-18. PubMed ID: 21761941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.
    Zeber-Lubecka N; Kulecka M; Ambrozkiewicz F; Paziewska A; Goryca K; Karczmarski J; Rubel T; Wojtowicz W; Mlynarz P; Marczak L; Tomecki R; Mikula M; Ostrowski J
    Gut Microbes; 2016 Sep; 7(5):397-413. PubMed ID: 27662586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated fecal microbiome-metabolome signatures reflect stress and serotonin metabolism in irritable bowel syndrome.
    Mujagic Z; Kasapi M; Jonkers DM; Garcia-Perez I; Vork L; Weerts ZZRM; Serrano-Contreras JI; Zhernakova A; Kurilshikov A; Scotcher J; Holmes E; Wijmenga C; Keszthelyi D; Nicholson JK; Posma JM; Masclee AA
    Gut Microbes; 2022; 14(1):2063016. PubMed ID: 35446234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome.
    Wei W; Wang HF; Zhang Y; Zhang YL; Niu BY; Yao SK
    World J Gastroenterol; 2020 Dec; 26(45):7153-7172. PubMed ID: 33362374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Gut Microbiota and Metabolites Signature in Patients With Irritable Bowel Syndrome.
    Zhu S; Liu S; Li H; Zhang Z; Zhang Q; Chen L; Zhao Y; Chen Y; Gu J; Min L; Zhang S
    Front Cell Infect Microbiol; 2019; 9():346. PubMed ID: 31681624
    [No Abstract]   [Full Text] [Related]  

  • 9. Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
    Maharshak N; Ringel Y; Katibian D; Lundqvist A; Sartor RB; Carroll IM; Ringel-Kulka T
    Dig Dis Sci; 2018 Jul; 63(7):1890-1899. PubMed ID: 29777439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study.
    Hong G; Li Y; Yang M; Li G; Qian W; Xiong H; Bai T; Song J; Zhang L; Hou X
    Neurogastroenterol Motil; 2020 Nov; 32(11):e13891. PubMed ID: 32449259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation.
    Tanaka Y; Yamashita R; Kawashima J; Mori H; Kurokawa K; Fukuda S; Gotoh Y; Nakamura K; Hayashi T; Kasahara Y; Sato Y; Fukudo S
    J Gastroenterol; 2022 Oct; 57(10):748-760. PubMed ID: 35908139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome.
    Tian Z; Zhuang X; Luo M; Yin W; Xiong L
    BMC Gastroenterol; 2020 Mar; 20(1):73. PubMed ID: 32178625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-omics Analysis of Gut Microbiota and Metabolites in Rats With Irritable Bowel Syndrome.
    Liu S; Si C; Yu Y; Zhao G; Chen L; Zhao Y; Zhang Z; Li H; Chen Y; Min L; Zhang S; Zhu S
    Front Cell Infect Microbiol; 2019; 9():178. PubMed ID: 31192167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption.
    Jeffery IB; Das A; O'Herlihy E; Coughlan S; Cisek K; Moore M; Bradley F; Carty T; Pradhan M; Dwibedi C; Shanahan F; O'Toole PW
    Gastroenterology; 2020 Mar; 158(4):1016-1028.e8. PubMed ID: 31843589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
    Duboc H; Rainteau D; Rajca S; Humbert L; Farabos D; Maubert M; Grondin V; Jouet P; Bouhassira D; Seksik P; Sokol H; Coffin B; Sabaté JM
    Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The networks of human gut microbe-metabolite associations are different between health and irritable bowel syndrome.
    Shankar V; Homer D; Rigsbee L; Khamis HJ; Michail S; Raymer M; Reo NV; Paliy O
    ISME J; 2015 Aug; 9(8):1899-903. PubMed ID: 25635640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis.
    Sun Q; Jia Q; Song L; Duan L
    Medicine (Baltimore); 2019 Feb; 98(7):e14513. PubMed ID: 30762787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome.
    Dior M; Delagrèverie H; Duboc H; Jouet P; Coffin B; Brot L; Humbert L; Trugnan G; Seksik P; Sokol H; Rainteau D; Sabate JM
    Neurogastroenterol Motil; 2016 Sep; 28(9):1330-40. PubMed ID: 27060367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome.
    Tang SQ; Wang YL; Xie ZY; Zhang Y; Guo Y; Gao KL; Mao TY; Xie CE; Li JX; Gao XY
    J Integr Med; 2021 May; 19(3):274-281. PubMed ID: 33775600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.